overweight
The weight-loss drug semaglutide - commonly sold under the brand names Ozempic and Wegovy - reduced cardiovascular events such as stroke and heart attack in adults with preexisting disease independent of weight loss. It also helped people keep their weight down for at least four years. That is according to two new analyses of a large trial presented at the European Congress on Obesity in Venice on Monday. Semaglutide is the main active ingredient in the popular weight-loss jabs Ozempic and Wegovy. It mimics the GLP-1 hormone which can signal that your body is full. The analyses looked at the S...
Euronews (English)
Danish pharmaceutical powerhouse Novo Nordisk has emerged as one of the standout performers among European mega-cap stocks in the early months of this year, boasting a robust 25% surge year to date. This performance further cemented Novo Nordisk's status as the largest European company by market capitalisation, reaching almost €550 billion and outpacing the market value of Tesla. Over the past year, the Danish pharma titan has seen its price jump by 80%, a rate of increase unmatched by any other European company valued at €100 billion or more. Novo Nordisk's growth driver: Weight-loss drug Weg...
Euronews (English)
More than one billion people in the world are now living with obesity, a new study published in The Lancet has found. Obesity, defined by a body mass index (BMI) equal to or exceeding 30 for adults, has become the main form of malnutrition in numerous countries. The prevalence of obesity has risen twice as rapidly among children and adolescents globally compared to adults. The study analysed the weight and height measurements of over 220 million people across 200 countries between 1990 to 2022. In 2022, the findings pointed to an estimated 879 million adults living with obesity - 504 million w...
Euronews (English)
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら